Disease · HP_0032807
Neonatal seizure
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Neonatal seizure. Diseases, record HP_0032807. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0032807
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Neonatal seizure
- Open Targets ID
- HP_0032807
- Highest stage of its drugs
- Phase 3, for 2 of its 4 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PHENOBARBITAL | CHEMBL40 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PHENOBARBITAL SODIUM | CHEMBL149972 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVETIRACETAM | CHEMBL1286 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BUMETANIDE | CHEMBL1072 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 2 | https://conductscience.org/library/genes/774 | Drugs and targets |
| SLC12A1 | Solute carrier family 12 member 1 | 1 | Sodium-(potassium)-chloride cotransporter 2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/6557 | Drugs and targets |
| SV2A | Synaptic vesicle glycoprotein 2A | 1 | Synaptic vesicle glycoprotein 2A modulator | Phase 2 | https://conductscience.org/library/genes/9900 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04320940 | Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures | Phase 3 | 4 | 2023-10-26 | Epilepsy, Benign Neonatal | PHENOBARBITAL SODIUM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT07401433 | Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital. | Not applicable | 260 | Neonatal Seizures | LEVETIRACETAM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05610085 | A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures | Phase 2 | 133 | Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn | LEVETIRACETAM | Its record names the disease | ClinicalTrials.gov | |
| NCT01224457 | Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients. | Not applicable | 52 | Neonatal Seizure | PHENOBARBITAL | Its record names the disease | ClinicalTrials.gov | |
| NCT01434225 | NEMO1:NEonatal Seizure Using Medication Off-patent | Phase 1/2 | 14 | Neonatal Seizures | BUMETANIDE, PHENOBARBITAL | Its record names the disease | ClinicalTrials.gov | |
| NCT03602118 | Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures | Phase 3 | 0 | Neonatal Seizure | PHENOBARBITAL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phenobarbital Sodium Injection 20mg vs Phenobarbital Sodium Injection 40mg: Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection. | 1 of 3 | 0 of 1 | 4 | NCT04320940 | Trial comparisons |
| Phenobarbital Sodium Injection 20mg vs Phenobarbital Sodium Injection 40mg: Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital. | 2 of 3 | 1 of 1 | 4 | NCT04320940 | Trial comparisons |
| Phenobarbital Sodium Injection 20mg vs Phenobarbital Sodium Injection 40mg: Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital. | 2 of 3 | 1 of 1 | 4 | NCT04320940 | Trial comparisons |
| Phenobarbital Sodium Injection 20mg vs Phenobarbital Sodium Injection 40mg: deaths from any cause | 0 of 3 | 0 of 1 | 4 | NCT04320940 | Trial comparisons |
| Phenobarbital Sodium Injection 20mg vs Phenobarbital Sodium Injection 40mg: serious adverse events | 1 of 3 | 0 of 1 | 4 | NCT04320940 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0032807
GET https://conductscience.org/api/diseases/v1/HP_0032807/drugs